第12届Waldenstrom巨球蛋白血症患者Bing-Neel综合征管理国际研讨会共识小组2报告。

IF 4.1 3区医学 Q1 HEMATOLOGY

Seminars in hematology Pub Date : 2025-04-01 DOI:10.1053/j.seminhematol.2025.04.005

Shayna Sarosiek , Anne-Marie L. Becking , Andrew Branagan , Simone Ferrero , Jahanzaib Khwaja , Eva Kimby , Damien Roos-Weil , Naohiro Sekiguchi , Marek Trneny , Shuhua Yi , Christopher J. Patterson , Christian Buske , Jeffrey V. Matous , Steven P. Treon , Monique C. Minnema

{"title":"第12届Waldenstrom巨球蛋白血症患者Bing-Neel综合征管理国际研讨会共识小组2报告。","authors":"Shayna Sarosiek , Anne-Marie L. Becking , Andrew Branagan , Simone Ferrero , Jahanzaib Khwaja , Eva Kimby , Damien Roos-Weil , Naohiro Sekiguchi , Marek Trneny , Shuhua Yi , Christopher J. Patterson , Christian Buske , Jeffrey V. Matous , Steven P. Treon , Monique C. Minnema","doi":"10.1053/j.seminhematol.2025.04.005","DOIUrl":null,"url":null,"abstract":"<div><div>Consensus panel 2 from the 12th International Workshop on Waldenstrom Macroglobulinemia was tasked with updating the guidelines on the diagnosis and management of patients with Bing-Neel syndrome (BNS). In this panel we have summarized the clinical symptoms that may be present with BNS, discussed the criteria required for diagnosis of BNS, made recommendations for follow-up imaging, and proposed revised guidelines for response assessment in BNS. The key recommendations from the 12th International Workshop on WM (IWWM-12) Consensus panel 2 include: (1) the establishment of zanubrutinib as a standard therapy for treatment of BNS; (2) recommendations on imaging and CSF evaluation during treatment and follow-up of BNS; and (3) revised response criteria in view of new data showing that malignant cells can persist in the CSF of many patients treated with BTK-inhibitors. New categorical response categories proposed include that for a Clinical Complete Response and Progressive Disease.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"62 2","pages":"Pages 85-89"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia\",\"authors\":\"Shayna Sarosiek , Anne-Marie L. Becking , Andrew Branagan , Simone Ferrero , Jahanzaib Khwaja , Eva Kimby , Damien Roos-Weil , Naohiro Sekiguchi , Marek Trneny , Shuhua Yi , Christopher J. Patterson , Christian Buske , Jeffrey V. Matous , Steven P. Treon , Monique C. Minnema\",\"doi\":\"10.1053/j.seminhematol.2025.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Consensus panel 2 from the 12th International Workshop on Waldenstrom Macroglobulinemia was tasked with updating the guidelines on the diagnosis and management of patients with Bing-Neel syndrome (BNS). In this panel we have summarized the clinical symptoms that may be present with BNS, discussed the criteria required for diagnosis of BNS, made recommendations for follow-up imaging, and proposed revised guidelines for response assessment in BNS. The key recommendations from the 12th International Workshop on WM (IWWM-12) Consensus panel 2 include: (1) the establishment of zanubrutinib as a standard therapy for treatment of BNS; (2) recommendations on imaging and CSF evaluation during treatment and follow-up of BNS; and (3) revised response criteria in view of new data showing that malignant cells can persist in the CSF of many patients treated with BTK-inhibitors. New categorical response categories proposed include that for a Clinical Complete Response and Progressive Disease.</div></div>\",\"PeriodicalId\":21684,\"journal\":{\"name\":\"Seminars in hematology\",\"volume\":\"62 2\",\"pages\":\"Pages 85-89\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0037196325000150\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0037196325000150","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

来自第12届华登斯特罗姆巨球蛋白血症国际研讨会的共识小组2的任务是更新Bing-Neel综合征（BNS）患者的诊断和管理指南。在这个小组中，我们总结了BNS可能出现的临床症状，讨论了BNS诊断所需的标准，提出了随访影像学的建议，并提出了BNS反应评估的修订指南。来自第12届WM国际研讨会（iwm -12）共识小组2的主要建议包括：(1)建立zanubrutinib作为治疗BNS的标准疗法；(2) BNS治疗及随访时影像学及脑脊液评价建议；(3)鉴于新的数据显示，在许多接受btk抑制剂治疗的患者脑脊液中，恶性细胞可以持续存在，修订了反应标准。新提出的分类反应类别包括临床完全缓解和进展性疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia

Consensus panel 2 from the 12th International Workshop on Waldenstrom Macroglobulinemia was tasked with updating the guidelines on the diagnosis and management of patients with Bing-Neel syndrome (BNS). In this panel we have summarized the clinical symptoms that may be present with BNS, discussed the criteria required for diagnosis of BNS, made recommendations for follow-up imaging, and proposed revised guidelines for response assessment in BNS. The key recommendations from the 12th International Workshop on WM (IWWM-12) Consensus panel 2 include: (1) the establishment of zanubrutinib as a standard therapy for treatment of BNS; (2) recommendations on imaging and CSF evaluation during treatment and follow-up of BNS; and (3) revised response criteria in view of new data showing that malignant cells can persist in the CSF of many patients treated with BTK-inhibitors. New categorical response categories proposed include that for a Clinical Complete Response and Progressive Disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in hematology 医学-血液学

CiteScore

6.20

自引率

2.80%

发文量

审稿时长

35 days

期刊介绍： Seminars in Hematology aims to present subjects of current importance in clinical hematology, including related areas of oncology, hematopathology, and blood banking. The journal''s unique issue structure allows for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering a variety of articles that present dynamic and front-line material immediately influencing the field. Seminars in Hematology is devoted to making the important and current work accessible, comprehensible, and valuable to the practicing physician, young investigator, clinical practitioners, and internists/paediatricians with strong interests in blood diseases. Seminars in Hematology publishes original research, reviews, short communications and mini- reviews.